Lyell Immunopharma appoints Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc.

Smital Shah appointed CFO and principal financial officer, effective March 9, 2026.
Initial base salary $500,000; target annual bonus up to 50% of base salary.
Granted option for 140,000 shares under 2021 Equity Incentive Plan; vesting 25% at 1 year then monthly.
Shah previously provided consulting to Lyell since Feb 2026; prior roles at ProQR, Gilead, and investment banks.
Will participate in Officer Severance Plan as Tier I Employee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.